化学療法薬 - 世界市場の考察、競合情勢、市場予測（2030年）

世界の化学療法薬の市場規模は、2024年～2030年の予測期間にCAGRで8.65％の成長が推定されています。市場は、さまざまながんの有病率の増加、がんの発症に関連する危険因子の増加、化学療法薬の製薬試験の増加、化学療法薬の安全性と有効性の向上への注目の高まりなどの要因によって活況を示す見込みであり、これらがさらに予測期間（2024年～2030年）の市場の顕著な収益成長につながることが見込まれす。

化学療法薬の市場力学

乳がん、肺がん、血液がんなどのさまざまながん種の有病率の上昇が、化学療法薬市場の主な促進要因となります。例えば、世界保健機関（WHO）（2022）のデータによると、2020年に世界で乳がん226万件、肺がん221万件、大腸がん193万件、前立腺がん141万件、胃がん109万件が報告されています。また、Global Cancer Observatory（2022）のデータによると、2020年に世界で約54万4,352例の非ホジキンリンパ腫と8万3,087例のホジキンリンパ腫が報告されています。同じ資料によると、2020年に全世界で約47万4,519例の白血病と約17万6,404例の多発性骨髄腫が報告されています。アルキル化剤、代謝拮抗剤、抗腫瘍性抗生物質などのさまざまな薬剤クラスに属する化学療法薬は、さまざまながんの治療と管理に広く利用されています。

化学療法薬市場の成長をもたらすもう1つの主な要因が、タバコの消費、喫煙、家族健康歴、過去のがん治療歴など、がんの発症に関連する危険因子の継続的な増加です。WHO（2022）によると、世界人口の約22.3%がタバコの消費に関与していることが記録されています。シガレットや葉巻のようなタバコ製品は、がんの主な危険因子の1つです。世界各国における喫煙人口の増加は、がん発症の全体的な負担を増加させています。例えば、Nanny State Index（NSI）（2022）によると、オーストリアの喫煙率は2020年に26.40％でした。Foundation for a Smoke-Free World（2022）が報告したデータによると、2019年のブラジルの成人喫煙者数は2,040万人でした。

化学療法薬の承認および上市の増加は、化学療法薬市場の成長にとって有益となる見込みです。例えば、2022年4月、BDR Pharmaceuticalsは胃がん治療薬としてFurmecilという抗がん剤の発売を発表しました。

しかし、化学療法薬に伴う副作用や化学療法における薬剤耐性の発生が、化学療法薬市場の成長抑制要因として作用する可能性があります。

化学療法薬市場は、COVID-19の拡大を阻止するために必要な措置としてロックダウンが実施されたため、短期的な市場成長の抑制が報告されました。原材料不足のため、化学療法薬の研究開発と製造に影響が出ました。化学療法薬の輸出入も国境閉鎖のために妨げられました。また、COVID-19患者の治療に注目がシフトしたため、病院の腫瘍科やさまざまな腫瘍科ベースの診療所が閉鎖され、その結果、がん患者の診断と治療が低下し、結果として化学療法薬市場の成長がしばらく鈍化しました。しかし、医療部門と製薬部門を含む産業全体の活動の再開に伴い、2024年～2030年の予測期間の化学療法薬の需要が増加しています。

化学療法薬市場のセグメント分析

化学療法薬市場の適応症セグメントでは、肺がんカテゴリが予測期間（2024年～2030年）に化学療法薬市場で大きな収益成長を記録する見込みです。

これは、肺がんの有病率の増加と、肺がんに対する化学療法薬の研究開発活動の活発化によるものと考えられます。Global Cancer Observatory（2020）によると、2020年に世界で約1,930万人の肺がん患者が診断されました。この資料はさらに、2040年までに世界中で約2,890万人の肺がん症例が新たに診断されると述べています。

当レポートでは、世界の化学療法薬市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 化学療法薬レポートのイントロダクション

第2章 化学療法薬市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 化学療法薬の主な要因の分析

• 化学療法薬市場の促進要因
• 化学療法薬市場の抑制要因と課題
• 化学療法薬市場の機会

第4章 化学療法薬市場のポーターのファイブフォース分析

第5章 化学療法薬市場に対するCOVID-19の影響分析

第6章 化学療法薬市場のレイアウト

• 薬剤クラス別
  • アルキル化剤
  • 有糸分裂阻害薬
  • 代謝拮抗薬
  • トポイソメラーゼ阻害薬
  • その他
• 適応症別
  • 肺がん
  • 乳がん
  • 前立腺がん
  • 大腸がん
• 投与経路別
  • 経口
  • 非経口
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第7章 化学療法薬市場の企業と製品のプロファイル

• Pfizer Inc.
• Johnson & Johnson Services Inc.
• GlaxoSmithKline PLC
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Sanofi S.A.
• Celgene Corporation
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Amgen
• Astellas Pharma Inc.
• AstraZeneca PLC
• Loxo Oncology Inc.
• GLS Pharma Pvt. Ltd.
• Beta Drugs
• TAIHO PHARMA CANADA, INC.
• Ipsen Pharma
• Aurobindo Pharma

第8章 KOLの見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightについて

第11章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Chemotherapy Drugs Market
• Table 3: Chemotherapy Drugs Market in Global (2021-2030)
• Table 4: Chemotherapy Drugs Market in Global by Drug Class (2021-2030)
• Table 5: Chemotherapy Drugs Market in Global by Indication (2021-2030)
• Table 6: Chemotherapy Drugs Market in Global by Route of Administration (2021-2030)
• Table 7: Chemotherapy Drugs Market in Global by Geography (2021-2030)
• Table 8: Chemotherapy Drugs Market in North America (2021-2030)
• Table 9: Chemotherapy Drugs Market in North America by Country (2021-2030)
• Table 10: Chemotherapy Drugs Market in the US (2021-2030)
• Table 11: Chemotherapy Drugs Market in Canada (2021-2030)
• Table 12: Chemotherapy Drugs Market in Mexico (2021-2030)
• Table 13: Chemotherapy Drugs Market in Europe (2021-2030)
• Table 14: Chemotherapy Drugs Market in Europe by Country (2021-2030)
• Table 15: Chemotherapy Drugs Market in France (2021-2030)
• Table 16: Chemotherapy Drugs Market in Germany (2021-2030)
• Table 17: Chemotherapy Drugs Market in the United Kingdom (2021-2030)
• Table 18: Chemotherapy Drugs Market in Italy (2021-2030)
• Table 19: Chemotherapy Drugs Market in Spain (2021-2030)
• Table 20: Chemotherapy Drugs Market in the Rest of Europe (2021-2030)
• Table 21: Chemotherapy Drugs Market in APAC (2021-2030)
• Table 22: Chemotherapy Drugs Market in APAC by Country (2021-2030)
• Table 23: Chemotherapy Drugs Market in China (2021-2030)
• Table 24: Chemotherapy Drugs Market in Japan (2021-2030)
• Table 25: Chemotherapy Drugs Market in India (2021-2030)
• Table 26: Chemotherapy Drugs Market in Australia (2021-2030)
• Table 27: Chemotherapy Drugs Market in South Korea (2021-2030)
• Table 28: Chemotherapy Drugs Market in Rest of APAC (2021-2030)
• Table 29: Chemotherapy Drugs Market in the Rest of the World (2021-2030)
• Table 30: Chemotherapy Drugs Market in RoW by Region (2021-2030)
• Table 31: Chemotherapy Drugs Market in the Middle East (2021-2030)
• Table 32: Chemotherapy Drugs Market in Africa (2021-2030)
• Table 33: Chemotherapy Drugs Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Chemotherapy Drugs Market
• Figure 3: Chemotherapy Drugs Market in Global (2021-2030)
• Figure 4: Chemotherapy Drugs Market in Global by Drug Class (2021-2030)
• Figure 5: Chemotherapy Drugs Market in Global by Indication (2021-2030)
• Figure 6: Chemotherapy Drugs Market in Global by Route of Administration (2021-2030)
• Figure 7: Chemotherapy Drugs Market in Global by Geography (2021-2030)
• Figure 8: Chemotherapy Drugs Market in North America (2021-2030)
• Figure 9: Chemotherapy Drugs Market in North America by Country (2021-2030)
• Figure 10: Chemotherapy Drugs Market in the US (2021-2030)
• Figure 11: Chemotherapy Drugs Market in Canada (2021-2030)
• Figure 12: Chemotherapy Drugs Market in Mexico (2021-2030)
• Figure 13: Chemotherapy Drugs Market in Europe (2021-2030)
• Figure 14: Chemotherapy Drugs Market in Europe by Country (2021-2030)
• Figure 15: Chemotherapy Drugs Market in France (2021-2030)
• Figure 16: Chemotherapy Drugs Market in Germany (2021-2030)
• Figure 17: Chemotherapy Drugs Market in the United Kingdom (2021-2030)
• Figure 18: Chemotherapy Drugs Market in Italy (2021-2030)
• Figure 19: Chemotherapy Drugs Market in Spain (2021-2030)
• Figure 20: Chemotherapy Drugs Market in the Rest of Europe (2021-2030)
• Figure 21: Chemotherapy Drugs Market in APAC (2021-2030)
• Figure 22: Chemotherapy Drugs Market in APAC by Country (2021-2030)
• Figure 23: Chemotherapy Drugs Market in China (2021-2030)
• Figure 24: Chemotherapy Drugs Market in Japan (2021-2030)
• Figure 25: Chemotherapy Drugs Market in India (2021-2030)
• Figure 26: Chemotherapy Drugs Market in Australia (2021-2030)
• Figure 27: Chemotherapy Drugs Market in South Korea (2021-2030)
• Figure 28: Chemotherapy Drugs Market in Rest of APAC (2021-2030)
• Figure 29: Chemotherapy Drugs Market in the Rest of the World (2021-2030)
• Figure 30: Chemotherapy Drugs Market in RoW by Region (2021-2030)
• Figure 31: Chemotherapy Drugs Market in the Middle East (2021-2030)
• Figure 32: Chemotherapy Drugs Market in Africa (2021-2030)
• Figure 33: Chemotherapy Drugs Market in South America (2021-2030)

Chemotherapy Drugs Market By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, And Others), By Route Of Administration (Oral And Parenteral), by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to increasing prevalence of different cancer types and increasing pharmaceutical trials for chemotherapy drugs

The global chemotherapy drugs market is estimated to grow at a CAGR of 8.65% during the forecast period 2024-2030. The chemotherapy drugs market is slated to witness prosperity owing to factors such as the growing prevalence of various cancer coupled with the increasing number of risk factors associated with cancer development, increasing pharmaceutical trials for chemotherapy drugs, and the growing focus on improving the safety and efficacy of chemotherapy drugs are further expected to result in the appreciable revenue growth in the chemotherapy drugs market during the forecast period (2024-2030).

Chemotherapy Drugs Market Dynamics:

The rising prevalence of different cancer types such as breast cancer, lung cancer, blood cancer, and others turns out to be the major factor for accelerating the chemotherapy drugs market. For instance, according to the data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020. Also, as per the Global Cancer Observatory 2022 data, globally around 544,352 cases of Non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020. As per the same source globally around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020. Chemotherapy drugs belonging to different drug classes such as alkylating agents, antimetabolites, anti-tumor antibiotics, and others are widely utilized in the treatment and management of different cancer.

Another key factor responsible for the growth of the chemotherapy drugs market is the continuous rise in the risk factors associated with the development of cancers including tobacco consumption, smoking, family history, previous cancer treatment, and others. According to WHO 2022, it was recorded that around 22.3% of the global population was involved in tobacco consumption. Tobacco-based products such as cigarettes and cigars are one of the major risk factors for cancers. The increasing rate of the smoking population in multiple countries around the world increases the overall burden of cancer development. For instance, as per the Nanny State Index (NSI) 2022, the rate of people smoking in Austria was 26.40% in 2020. As per the data reported by Foundation for a Smoke-Free World 2022, there were 20.4 million adult smokers in Brazil in 2019.

The increasing number of approval and launches for chemotherapy drugs is going to be beneficial for the growth of the chemotherapy drugs market. For example, in April 2022, BDR Pharmaceuticals announced the launch of an anti-cancer drug named Furmecil for the treatment of gastric cancer.

However, side-effects associated with chemotherapy drugs and the occurrence of drug resistance in chemotherapy may act as restraining factors to the chemotherapy drugs market growth.

The chemotherapy drugs market reported a short period of restraint in the market growth due to the implementation of the lockdown as a necessary step to stop the spread of COVID-19 infection. Owing to the shortage of raw materials, R&D and manufacturing of chemotherapy drugs were affected. The import and export of chemotherapy drugs were also hampered due to border closures. Also, the oncology departments in hospitals and various oncology-based clinics were closed down due to shifted primary focus on treating patients suffering from COVID- 19 which in turn led to the decline in diagnosis and treatment of cancer patients, ultimately slowing the chemotherapy drugs market growth for a while. However, with the resumption of activities across industries including the healthcare and pharmaceutical sector, there has been a rising demand for chemotherapy drugs during the forecast period from 2024-2030.

Chemotherapy Drugs Market Segment Analysis:

Chemotherapy Drugs Market by Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, and Others], Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, and Others), Route of Administration (Parenteral, and Oral), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the indication segment of the chemotherapy drugs market, the lung cancer category is projected to register a significant growth in revenue in the chemotherapy drugs market during the forecast period (2024-2030).

This can be ascribed to the increasing prevalence of lung cancer and increasing chemotherapy drug research and development activities for lung cancer. As per the Global Cancer Observatory 2020, globally around 19.3 million lung cancer cases were diagnosed in 2020. The source further stated that by 2040, about 28.9 million new cases of lung cancer will be diagnosed across the world.

Additionally, the rising number of pharmaceutical trials of chemotherapy drugs for lung cancer may assist in the growing demand for chemotherapy drugs. For example, Incyte Corporation is currently conducting a Phase III clinical trial for assessing the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC), and the trial is estimated to get complete by August 2025.

Therefore, considering the rising prevalence of lung cancer and the increasing focus of companies on developing and launching new chemotherapy drugs for lung cancer, the indication category is expected to generate considerable revenue thereby pushing the overall growth of global chemotherapy drugs during the forecast period.

North America is expected to dominate the overall Chemotherapy Drugs Market:

Among all the regions, North America is expected to lead in revenue generation in the global chemotherapy drugs market. This can be ascribed to the presence of a large patient pool associated with cancer, an increase in the number of smokers, and a highly potent market in terms of product development and launches, high consumer awareness, and the local presence of key market players among other factors in the region.

One of the prominent factors supporting the growth of the North America cancer diagnostic market is the rising prevalence of cancer. As per the figures mentioned by the American Cancer Society 2022, it was estimated that around 1.9 million new cancer cases were diagnosed in the United States in 2022. Also, according to the data provided by the Centers for Disease Control and Prevention (CDC) in 2022, around 1,752,735 new cases of cancer were reported in the US in 2019. As per Globocan 2022 data, there were around 61,152 new cases of leukemia recorded in 2020 in the United States. As per the same source around 73, 652 cases of Non-Hodgkin lymphoma and 8,107 new cases of Hodgkin lymphoma were recorded in 2020 in the US.

Another factor contributing to the growth of the chemotherapy drugs market is the continued rise in the number of individuals involved in smoking. For instance, as per the Centers for Disease Control and Prevention 2022, approximately 40 million people smoke cigarettes in the US. As per the same source, every day nearly 1,600 US youth aged 18 years or younger smoke their first cigarette. Smoking affects both smokers and non-smokers eventually increasing their risk for cancer such as lung, oral, and blood cancer, and others.

Therefore, owing to the above-mentioned factors, the chemotherapy drugs market is expected to bolster in the United States during the forecast period.

Chemotherapy Drugs Market Key Players:

Some of the key market players operating in the chemotherapy drugs market include Johnson & Johnson Services Inc., Pfizer Inc., GlaxoSmithKline PLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., Sanofi S.A., Celgene Corporation, Bristol-Myers Squibb Company, AbbVie Inc., Amgen, Loxo Oncology Inc., AstraZeneca PLC, Astellas Pharma Inc., GLS Pharma Pvt. Ltd., TAIHO PHARMA CANADA, INC., Beta Drugs, TAIHO PHARMA CANADA, INC., Ipsen Pharma, Aurobindo Pharma, and others.

Recent Developmental Activities in the Chemotherapy Drugs Market:

In June 2020, the US Food and Administration approved two new drugs, namely olaparib (Lynparza) and rucaparib (Rubraca) for the treatment of prostate cancer.

In May 2020, FDA approved the encorafenib (Braftovi) drug for the treatment of some patients suffering from colorectal cancer.

In October 2022, (Verzenio) abemaciclib was approved by US FDA as the first and only CDK 4/6 inhibitor for some people suffering from the risk of HR+ HER2- High-Risk Early Breast Cancer.

Key Takeaways from the Chemotherapy Drugs Market Report Study

Market size analysis for current chemotherapy drugs market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the chemotherapy drugs market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global chemotherapy drugs market.

Various opportunities available for the other competitor in the chemotherapy drugs market space.

What are the top-performing segments in 2023? How these segments will perform in 2027?

Which are the top-performing regions and countries in the current chemotherapy drugs market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for chemotherapy drugs market growth in the coming future?

Target Audience who can be benefited from this Chemotherapy Drugs Market Report Study

Chemotherapy drugs providers

Research organizations and consulting companies

Chemotherapy drugs -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in chemotherapy drugs.

Various end users who want to know more about the chemotherapy drugs market and the latest developments in the chemotherapy drugs market.

Frequently Asked Questions for the Chemotherapy Drugs Market:

1. What are chemotherapy drugs?

Chemotherapy drugs belonging to different drug classes such as mitotic inhibitors, alkylating agents, antimetabolites, topoisomerase inhibitors, and others are intended for killing cancer cells.

2. What is the market for global chemotherapy drugs?

The global chemotherapy drugs market is estimated to grow at a CAGR of 8.65% during the forecast period 2024-2030.

3. What are the drivers for the global chemotherapy drugs market?

The chemotherapy drugs market is slated to witness prosperity owing to factors such as the growing prevalence of different cancer types, the rising number of risk factors for cancer, the increasing number of pharmaceutical trials coupled with increasing approval and launches for chemotherapy drugs, and the growing focus on improving the safety, efficacy, and affordability of chemotherapy drugs are further expected to result in the appreciable revenue growth in the chemotherapy drugs market during the forecast period (2024-2030).

4. Who are the key players operating in the global chemotherapy drugs market?

Some of the key market players operating in the global chemotherapy drugs market include Johnson & Johnson Services Inc., Pfizer Inc., GlaxoSmithKline PLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., Sanofi S.A., Celgene Corporation, Bristol-Myers Squibb Company, AbbVie Inc., Amgen, Loxo Oncology Inc., AstraZeneca PLC, Astellas Pharma Inc., GLS Pharma Pvt. Ltd., TAIHO PHARMA CANADA, INC., Beta Drugs, TAIHO PHARMA CANADA, INC., Ipsen Pharma, Aurobindo Pharma, and others.

5. Which region has the highest share in the chemotherapy drugs market?

North America is expected to dominate the overall chemotherapy drugs market during the forecast period, 2022 to 2027. This can be ascribed to the presence of a large patient pool associated with cancer, a rise in several smokers, high-tech medical facilities, government initiatives, a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

Table of Contents

1.Chemotherapy Drugs Report Introduction

2. Chemotherapy Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Chemotherapy Drugs Key Factors Analysis

• 3.1. Chemotherapy Drugs Market Drivers
  • 3.1.1. Rising prevalence of various cancer
  • 3.1.2. Increasing risk factors for cancer
  • 3.1.3. Increasing pharmaceutical trials for chemotherapy drugs
• 3.2. Chemotherapy Drugs Market Restraints and Challenges
  • 3.2.1. Side effects associated with chemotherapy
  • 3.2.2. Drug Resistance in chemotherapy
• 3.3. Chemotherapy Drugs Market Opportunities
  • 3.3.1. Advances in lipid-based nanoparticles for cancer chemotherapy
  • 3.3.2. Exploring the effect of chemotherapy drugs on immune system disorders

4. Chemotherapy Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

5. COVID-19 Impact Analysis on Chemotherapy Drugs Market

6. Chemotherapy Drugs Market Layout

• 6.1. By Drug Class
  • 6.1.1. Alkylating Agents
  • 6.1.2. Mitotic Inhibitors
  • 6.1.3. Antimetabolites
  • 6.1.4. Topoisomerase Inhibitors
  • 6.1.5. Others
• 6.2. By Indication
  • 6.2.1. Lung Cancer
  • 6.2.2. Breast Cancer
  • 6.2.3. Prostate Cancer
  • 6.2.4. Colorectal Cancer
  • 6.2.5. Others
• 6.3. By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. By Geography
  • 6.4.1. North America
    • 6.4.1.1. United States Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.1.2. Canada Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.1.3. Mexico Chemotherapy Drugs Market in USD million (2021-2030)
  • 6.4.2. Europe
    • 6.4.2.1. France Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.2.2. Germany Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.2.3. United Kingdom Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.2.4. Italy Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.2.5. Spain Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.2.6. Rest of Europe Chemotherapy Drugs Market in USD million (2021-2030)
  • 6.4.3. Asia-Pacific
    • 6.4.3.1. China Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.3.2. Japan Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.3.3. India Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.3.4. Australia Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.3.5. South Korea Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.3.6. Rest of Asia Pacific Chemotherapy Drugs Market in USD million (2021-2030)
  • 6.4.4. Rest of the World (RoW)
    • 6.4.4.1. Middle East Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.4.2. Africa Chemotherapy Drugs Market in USD million (2021-2030)
    • 6.4.4.3. South America Chemotherapy Drugs Market in USD million (2021-2030)

7. Chemotherapy Drugs Market Company and Product Profiles

• 7.1. Pfizer Inc.
  • 7.1.1. Company Overview
  • 7.1.2. Company Snapshot
  • 7.1.3. Financial Overview
  • 7.1.4. Product Listing
  • 7.1.5. Entropy
• 7.2. Johnson & Johnson Services Inc.
  • 7.2.1. Company Overview
  • 7.2.2. Company Snapshot
  • 7.2.3. Financial Overview
  • 7.2.4. Product Listing
  • 7.2.5. Entropy
• 7.3. GlaxoSmithKline PLC
  • 7.3.1. Company Overview
  • 7.3.2. Company Snapshot
  • 7.3.3. Financial Overview
  • 7.3.4. Product Listing
  • 7.3.5. Entropy
• 7.4. Eli Lilly and Company
  • 7.4.1. Company Overview
  • 7.4.2. Company Snapshot
  • 7.4.3. Financial Overview
  • 7.4.4. Product Listing
  • 7.4.5. Entropy
• 7.5. F. Hoffmann-La Roche Ltd
  • 7.5.1. Company Overview
  • 7.5.2. Company Snapshot
  • 7.5.3. Financial Overview
  • 7.5.4. Product Listing
  • 7.5.5. Entropy
• 7.6. Novartis AG
  • 7.6.1. Company Overview
  • 7.6.2. Company Snapshot
  • 7.6.3. Financial Overview
  • 7.6.4. Product Listing
  • 7.6.5. Entropy
• 7.7. Merck & Co. Inc.
  • 7.7.1. Company Overview
  • 7.7.2. Company Snapshot
  • 7.7.4. Financial Overview
  • 7.7.4. Product Listing
  • 7.7.5. Entropy
• 7.8. Sanofi S.A.
  • 7.8.1. Company Overview
  • 7.8.2. Company Snapshot
  • 7.8.3. Financial Overview
  • 7.8.4. Product Listing
  • 7.8.5. Entropy
• 7.9. Celgene Corporation
  • 7.9.1. Company Overview
  • 7.9.2. Company Snapshot
  • 7.9.3. Financial Overview
  • 7.9.4. Product Listing
  • 7.9.5. Entropy
• 7.10. Bristol-Myers Squibb Company
  • 7.10.1. Company Overview
  • 7.10.2. Company Snapshot
  • 7.10.3. Financial Overview
  • 7.10.4. Product Listing
  • 7.10.5. Entropy
• 7.11. AbbVie Inc.
  • 7.11.1. Company Overview
  • 7.11.2. Company Snapshot
  • 7.11.3. Financial Overview
  • 7.11.4. Product Listing
  • 7.11.5. Entropy
• 7.12. Amgen
  • 7.12.1. Company Overview
  • 7.12.2. Company Snapshot
  • 7.12.3. Financial Overview
  • 7.12.4. Product Listing
  • 7.12.5. Entropy
• 7.13. Astellas Pharma Inc.
  • 7.13.1. Company Overview
  • 7.13.2. Company Snapshot
  • 7.13.3. Financial Overview
  • 7.13.4. Product Listing
  • 7.13.5. Entropy
• 7.14. AstraZeneca PLC
  • 7.14.1. Company Overview
  • 7.14.2. Company Snapshot
  • 7.14.3. Financial Overview
  • 7.14.4. Product Listing
  • 7.14.5. Entropy
• 7.15. Loxo Oncology Inc.
  • 7.15.1. Company Overview
  • 7.15.2. Company Snapshot
  • 7.15.3. Financial Overview
  • 7.15.4. Product Listing
  • 7.15.5. Entropy
• 7.16. GLS Pharma Pvt. Ltd.
  • 7.16.1. Company Overview
  • 7.16.2. Company Snapshot
  • 7.16.3. Financial Overview
  • 7.16.4. Product Listing
  • 7.16.5. Entropy
• 7.17. Beta Drugs
  • 7.17.1. Company Overview
  • 7.17.2. Company Snapshot
  • 7.17.3. Financial Overview
  • 7.17.4. Product Listing
  • 7.17.5. Entropy
• 7.18. TAIHO PHARMA CANADA, INC.
  • 7.18.1. Company Overview
  • 7.18.2. Company Snapshot
  • 7.18.3. Financial Overview
  • 7.18.4. Product Listing
  • 7.18.5. Entropy
• 7.19. Ipsen Pharma
  • 7.19.1. Company Overview
  • 7.19.2. Company Snapshot
  • 7.19.3. Financial Overview
  • 7.19.4. Product Listing
  • 7.19.5. Entropy
• 7.20. Aurobindo Pharma
  • 7.20.1. Company Overview
  • 7.20.2. Company Snapshot
  • 7.20.3. Financial Overview
  • 7.20.4. Product Listing
  • 7.20.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us